EP1720825B1 - Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh - Google Patents

Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh Download PDF

Info

Publication number
EP1720825B1
EP1720825B1 EP05707941A EP05707941A EP1720825B1 EP 1720825 B1 EP1720825 B1 EP 1720825B1 EP 05707941 A EP05707941 A EP 05707941A EP 05707941 A EP05707941 A EP 05707941A EP 1720825 B1 EP1720825 B1 EP 1720825B1
Authority
EP
European Patent Office
Prior art keywords
benzoic acid
propionylamino
hydrogen
trifluoromethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05707941A
Other languages
German (de)
English (en)
Other versions
EP1720825A1 (fr
Inventor
Stig Jönsson
Gunnar Andersson
Ulf Wellmar
Ingela Fritzon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chelsea Therapeutics Inc
Original Assignee
Active Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech AB filed Critical Active Biotech AB
Priority to PL05707941T priority Critical patent/PL1720825T3/pl
Publication of EP1720825A1 publication Critical patent/EP1720825A1/fr
Application granted granted Critical
Publication of EP1720825B1 publication Critical patent/EP1720825B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C233/63—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Definitions

  • the present invention relates to novel anthranilic acid derivatives, which are potent inhibitors of dihydroorotate dehydrogenase (DHODH), to be used for clinical treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia.
  • DHODH dihydroorotate dehydrogenase
  • These compounds and pharmaceutical compositions of this invention are particularly useful for preventing and treating acute and chronic inflammation, rheumatoid arthritis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, transplant rejection and malignant neoplastic disease. More particularly, the present invention relates to novel derivatives suitable for the treatment of rheumatoid arthritis and transplant rejection.
  • RA Rheumatoid arthritis
  • RA is a chronic inflammatory and destructive joint disease that affects 0.5-1.0% of the population in the industrialised world.
  • RA is a polyarthritis and in the disease virtually all peripheral joints might be affected.
  • extra-articular involvement is another hallmark of RA and this ranges from rheumatoid nodules to life threatening vasculitis.
  • autoimmunity plays a pivotal role in its chronic-ity and progression (Breedveld, 1998). Many pathways involved in the generation of the disease have been recognised and some of these have been unequivocally identified as important by therapeutic proof of principle studies.
  • RA RA-related RA
  • Drug therapy for RA rests on two principal approaches: symptomatic treatment with non-steroidal antiinflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs).
  • NSAIDs only interfere with a small segment of the inflammatory cascade (prostaglandin generation) but do not interfere with the underlying immuno-inflammatory events.
  • DMARDs modify the disease process in all these respects.
  • DMARDs can be divided into small molecules and biological agents.
  • DMARDs small-molecule DMARDs are used today in RA therapy. In fact methotrexate is still the most commonly used DMARD and sulphasalazine was the second most common DNLARD used in Europe during the 1990s. Thus, a number of drugs have been developed and used in RA therapy each targeting a specific pathway of importance to the generation of the disease.
  • Leflunomide is in vivo rapidly metabolised to the active metabolite A771726, which inhibits dihydroorotate-dehydrogenase (DHODH), an enzyme that is pivotally involved in de novo pyrimidine synthesis. Inhibition of this enzyme inhibits the growth of (pathologically) fast proliferating cells.
  • DHODH dihydroorotate-dehydrogenase
  • the most important cell types for the immune response, the lymphocytes use exclusively the synthesis of pyrimidines for their growth and react particularly to DHODH inhibition (Batt, 1999; Cherwinski et al., 1995).
  • Substances that inhibit growth of lymphocytes are important medicaments for the treatment of autoimmune diseases including RA.
  • the DHODH inhibiting leflunomide is the first medication of this class of compounds for the treatment ofRA.
  • leflunomide has provided clinical proof of concept for the mechanism, but due to its side effects, e.g., liver abnormalities and influence on fertility, it is far from optimal for treatment of RA.
  • EP0497740 discloses benzyloxyphenyl derivatives of general formula (A)
  • R 1 and R 3 are methoxy, and the benzyloxy moiety is in meta -position in respect to R 6 .
  • R 6 is carboxy or an ester group,
  • R 5 is hydroxy or acetylamino, especially hydroxy.
  • EP0815087 discloses trisubstituted phenyl derivatives of general formula (B)
  • Said patent concerns compounds for the treatment of inflammatory and proliferative skin diseases and cancer.
  • the compounds are to be administered topically or in divided doses up to four times a day.
  • R 1 and R 2 are methoxy
  • W is CH 2 CH 2
  • R 3 and R 4 together with the phenyl ring form a condensed ring system.
  • R 1 and R 2 are the same or different and represent alkoxy, alkyl or alkenyloxy, R 3 is i.a. alkoxy and R 4 is i.a. acylamino.
  • a primary objective of the present invention is to provide structurally novel anthranilic acid derivatives, which by virtue of their pharmacological profile, with high potency in experimental models and low level of side effects, are considered to be of value in the treatment of autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia.
  • the invention refers to novel compounds, which inhibit DHODH, to a process for their manufacture and pharmaceutical compositions containing them, and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting DHODH.
  • the compounds may be used for preventing and treating, but not restricted to, acute and chronic inflammation, rheumatoid arthritis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, transplant rejection and malignant neoplastic disease. More particularly, the present invention relates to novel derivatives suitable for the treatment of rheumatoid arthritis and transplant rejection.
  • the present invention is directed to compounds of formula (I)
  • Y is a pharmaceutically acceptable cation it may be selected from e.g. Li + , Na + , K + , Mg 2+ , Ca 2+ and Zn 2+ .
  • Y is a divalent cation, it is to be understood that the salt may contain two anthranilic acid derivative moieties for each cation.
  • the compounds of formula (I) unexpectedly displayed potent inhibition of the enzyme DHODH.
  • Compounds of formula (I) wherein the acylamino group adjacent to the carboxylic acid group was replaced by a hydroxy group demonstrated no DHODH inhibition.
  • Exchanging in a compound wherein the acylamino moiety is acetylamino the acetylamino moiety for propionylamino or cyclopropylcarbonylamino increased the inhibitory effect up to a 10-fold.
  • Further addition of bulk strongly reduced the DHODH inhibition, reflecting a specific interaction with a size dependent enzyme pocket.
  • the compounds of formula (I) may be prepared by the following methods:
  • the compounds of formula (I) may be prepared by known methods, for example, by aromatic nucleophilic substitution of nitro-activated fluoro derivatives (II) in a suitable solvent such as acetonitrile or apolar aprotic solvent, e.g., DMF.
  • the reduction of the resultant nitro derivative to corresponding amino derivative may be accomplished by use of anhydrous copper(II)acetate activated sodium borohydride in ethanol at room temperature.
  • This reduction agent is particularly useful for reduction of sulphur containing nitro derivatives as described by Mathis et al. (2003).
  • the resultant amino derivative may be readily transformed to target compound (I) by acylation.
  • Suitable acylating reagents are for example anhydrides and acyl chlorides (Method J ). Simple alkaline hydrolysis of the ester functionality provides the acidic function.
  • the yields are generally in the range of 5-80 %, with lower yields for ortho-substituted aryl compounds.
  • Simple alkaline hydrolysis of the ester functionality provides the acidic function.
  • Aromatic nucleophilic substitution may also be applied in the preparation of 2-substituted amino derivatives.
  • the reaction conditions are similar to the conditions in method A, with a good yield of the intermediate nitro derivative. This may then be reduced to the corresponding amino derivative, which may be reacted with phenylboronic acid derivatives as described in Method B, or alkylated via reductive alkylation as described in Method D.
  • the compound of formula (I) wherein R 2 is NH 2 may be further transformed by acylation thereof.
  • Suitable acylating reagents are for example anhydrides and acyl chlorides (Method J). Simple alkaline hydrolysis of the ester functionality provides the acidic function.
  • the compounds of formula (I), may also be prepared by reacting a compound of formula (IV) or corresponding acid, wherein W is a nucleophilic group, with a benzylic reagent wherein A is a leaving group, e.g., bromide, chloride, mesyloxy or tosyloxy.
  • A is a leaving group, e.g., bromide, chloride, mesyloxy or tosyloxy.
  • the substitution may be carried out in a suitable solvent such as a polar aprotic solvent, e.g., acetone or DMF, in the presence of an alkali metal carbonate, e.g., potassium carbonate.
  • Simple alkaline hydrolysis of the ester functionality provides the acidic junction.
  • the N-acylanthranilic ester (IV) may be prepared from commercially available isatoic anhydrides or by reacting commercially available 5-substituted anthranilic acids with phosgene to provide isatoic anhydrides.
  • the reaction of an isatoic anhydride with anhydrous alcohols, in the presence of small quantities of sodium methoxide provides the corresponding anthranilic ester in a good yield (Staiger and Miller, 1959).
  • Suitable acylating reagents to transform the anthranilic ester to the amide (IV) are for example acid anhydrides and acyl chlorides (A is a leaving group).
  • Compounds of formula (IV) may also be prepared from commercially available 5-substituted anthranilic acids. Reaction of such an acid with anhydrous alcohols in the presence of thionyl chloride provides the anthranilic ester which then can give amides IV according to method J.
  • nuclear magnetic resonance data were recorded at 400 MHz using a Bruker ARX 400 spectrometer.
  • the spectra were obtained in CDCl 3 , CD 3 OD and DMSO-d 6 and the shift scale was referenced to TMS, defined as 0.00 ppm.
  • This compound was prepared essentially as described by Hutchinson et al. 1996.
  • Methyl anthranilate (30.9 g; 205 mmols) and benzyl alcohol (4.43 g; 40,9 mmols) were dissolved in 50 mL of p-xylene.
  • Montmorillonite (1.3 g), activated with hydrochloric acid, was added to the reaction mixture, which was then heated to boiling. The water produced during the reaction was collected using a Dean-Starck-apparatus. After three hours the solvent and the excess of methyl anthranilate were distilled off at reduced pressure. Chromatography using silica gel 60 and heptane/ethyl acetate (19/1 -> 9/1) as eluent afforded 430 mg (4.4%) of the desired methyl 5-benzylanthranilate.
  • Methyl 5-benzylanthranilate (300 mg; 1.24 mmols) was dissolved in 7 mL of chloroform and propionyl chloride (344mg; 3.72 mmols) was added and the reaction mixture was left at room temperature for 18 hours.
  • Aqueous saturated sodium bicarbonate (5 mL) was added to the reaction mixture whereafter the organic phase was separated, dried over magnesium sulphate, filtered and evaporated to dryness.
  • the resulting yellow oil was dissolved in 5 mL of methanol and aqueous sodium hydroxide (1 M, 5 mL) was added. The reaction mixture was then heated to 60°C for two hours. After cooling to room-temperature the reaction mixture was acidified with 20 mL of hydrochloric acid (1M).
  • 5-nitroisatoic anhydride (20.8 g, 0.1 mol) was heated to reflux with sodium methoxide (0.5 g, 0.01mol) in methanol (600 mL). After 1 h, the solvent was evaporated under vacuum and the residue dissolved in 1,2-dichloroethane (400 mL), washed with cold water and dried over MgSO 4 . Cyclopropanecarbonyl chloride (20.9 g, 0.2 mol) was added to the solution and then heated at 80 °C for 4.5 h. The mixture was allowed to cool and water (200 mL) was added under vigorous stirring.
  • T cell proliferation was studied in a functional assay.
  • a human T lymphoblast cell line (Jurkat) was cultured in the presence and absence of DHODH inhibiting compounds.
  • Jurkat cells were seeded in microtiterplates at a concentration of 5 x 10 5 / mL in RPMI 1640 growth media supplemented with ultraglutamin, 10% fetal calf serum, 1 mM sodium pyruvat, 10 mM HEPES and 0.1 mg/mL gentamycin.
  • a dilution series of ten different concentrations of inhibitor was added to the wells and the plates were kept in a cell incubator for 3 days.
  • the cultures were pulsed with 10 pl/well 0.1 Ci/mmol 3 H-TdR and then harvested on filter papers and counted with a ⁇ -counter.
  • the IC 50 values for each compound were calculated from the obtained dose response curves. Adding 50 ⁇ M uridine to the wells monitored the specificity for the mechanism. This reverses the antiproliferative effect by bypassing the DHODH enzyme using an external source of pyrimidine.
  • Inbred rat strains male PVG (RT1 c ) (100-149 g) and DA (RT1 av1 ) (180-240 g) rats were used as donors and recipients, respectively.
  • Heterotopic cardiac transplantation was performed with a non-suture cuff technique.
  • the donor heart was transplanted to the recipient's right vessels of the neck, the aortic root being anastomosed to the common carotid artery and the pulmonary artery to the jugular vein.
  • the graft veins were ligated. Graft survival was monitored twice daily and rejection was defined as cessation of palpable cardiac graft beats.
  • Parallel subgroups of recipients were treated orally with a gastric feeding catheter once daily for ten consecutive days. First day of treatment was the day of transplantation and the rats were treated a few minutes before transplantation.
  • mice Female mice (SJL/N Tac) were given a single intravenous or oral dose of a mixture of 4 or 6 compounds per cassette (nominal dose: 1 mg/kg/compound).
  • the test items were formulated in physiological saline/5% Cremophor ® to a final concentration of each 0.1 mg/mL.
  • Blood samples were collected from vena cava (terminal bleed) into sodium heparinised tubes.
  • the dose formulations and plasma concentrations of each compound were determined by LC-MS/MS.
  • the pharmacokinetic parameters were determined by non-compartmental analysis using WinNonlin Professional (version 4.0.1).
  • EP0497740 discloses compounds that are stated to be useful as antihyperproliferative/ antiinflammatory and anticancer agents.
  • the compound disclosed as most preferred is 5-(2,5-diruethoxy-benzyloxy)-2-hydroxy-benzoic acid methyl ester.
  • the present inventors found 5-(2,5-dimethoxy-benzyloxy)-2-hydroxy benzoic acid to be inactive as a DHODH inhibitor.
  • EP0497740 also discloses the compound 2-acetylamino-5-(2,5-dimethoxy-benzyloxy)-benzoic acid methyl ester.
  • the compound 2-acetylamino-5-(2,5-dimethoxy-benryloxy)-benzoic acid (hereinafter called compound G) has been tested and found to display only a weak inhibitory effect on T-cell proliferation, see Table 1.
  • EP0815087 discloses compounds structurally related to compounds of formula (I) that are stated to be useful for the treatment of proliferative and/or inflammatory disorders and cancer, e.g., 2-acetylamino-5-[2-(2,5-dimethoxy-phenyl)-ethyl]-benzoic acid methyl ester.
  • 2-Acetylamino-5-[2-(2,5-dimethoxy-phenyl)-ethyl]-benzoic acid hereinafter called compound H
  • compound H 2-Acetylamino-5-[2-(2,5-dimethoxy-phenyl)-ethyl]-benzoic acid
  • compound J The compound 2-propionylamino-5-[2-(2-trifluoromethyl-phenyl)-ethyl]-benzoic acid (hereinafter called compound J) is included as a reference compound.
  • Compound J displayed a weak antiproliferative effect, see Table 1.
  • T cell proliferation was studied in a functional assay.
  • Table 1 exemplifies the invention, without limiting the scope thereof.
  • a human T lymphoblast cell line (Jurkat) was cultured in the presence of the compound to be screened. The IC 50 value for each compound was calculated from the dose response curve. Adding uridine was used to monitor the specificity of the DHODH mechanism. Table 1. Inhibition of T-cell proliferation in vitro.
  • the compounds of the present invention possess advantageous pharmacokinetic properties and high oral bioavailability.
  • the clearance (CL) and half-life (t 1 ⁇ 2 ) of representative compounds in the mouse following i.v. administration are shown in Table 2.
  • Table 2 exemplifies the invention, without limiting the scope thereof.
  • compositions comprising an effective amount of the active ingredient and a suitable pharmaceutically acceptable carrier.
  • Such compositions may take a variety of forms, e.g., solutions, suspensions, emulsions, tablets, capsules, and powders prepared for oral administration, sterile solutions for parental administration, and suppositories for rectal administration or suitable topical formulations. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described, for example, in " Pharmaceuticals - The Science of Dosage Form Design", M.B. Aulton, Churchill Living-stone, 1988 .
  • a suitable daily dose for use in the treatment of a disease selected from autoimmune diseases, inflammatory diseases, organ transplant rejection and malignant neoplasia is contemplated to vary between 0.005 mg/kg to about 10 mg/kg body weight, in particular between 0.025 mg/kg to 2 mg/kg body weight, depending upon the specific condition to be treated, the age and weight of the specific patient, and the specific patient's response to the medication.
  • the exact individual dosage, as well as the daily dosage, will be determined according to standard medical principles under the direction of a physician.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

  1. Composé de formule (I)
    Figure imgb0027
     dans laquelle
    X est CH2, NH, 0, S, CH=CH, C≡C, NHCH2 ou OCH2, où l'atome d'azote ou d'oxygène est lié au cycle A ; CH2O ou CH2S où l'atome d'oxygène ou de soufre est lié au cycle B ;
    Y est un hydrogène, un alkyle en C1-C4 linéaire ou ramifié ou un cation inorganique pharmaceutiquement acceptable ;
    R1 est un éthyle ou un cyclopropyle ;
    R2 et R3 sont identiques ou différents et représentent un hydrogène, un alkylthio en C1-C4 linéaire ou ramifié, NHR4, NR4R5, un trifluorométhyle, un trifluorométhoxy, NHCOR6, un phényle, un phénoxy, un phénylthio ou un phénylamino ; où le groupe phényle est facultativement monosubstitué par un fluoro ;
    R4 et R5 sont indépendamment un hydrogène ou un alkyle en C1-C4 linéaire ou ramifié ; ou
    R4 et R5, conjointement avec l'azote auquel ils sont liés, forment un cycle à 5 ou 6 chaînons
    Figure imgb0028
    Z est CH2, O, NH ou NCH3 ; et
    R6 est un alkyle en C1-C3, un phénylamino ou un phényle facultativement monosubstitué par un alcoxy en C1-C2 ou un fluoro ;
    étant entendu que R2 et R3 ne sont pas tous les deux un hydrogène lorsque X est OCH2.
  2. Composé selon la revendication 1, dans lequel
    X est CH2, O, S, CH=CH, OCH2, CH2O ou CH2S ;
    Y est un hydrogène, un alkyle en C1-C4 linéaire ou ramifié ou un cation inorganique pharmaceutiquement acceptable ;
    R2 et R3 sont identiques ou différents et représentent un hydrogène ou des substituants aux positions 2, 3 ou 5, choisis parmi NHR4, NR4R5, un trifluorométhyle, un trifluorométhoxy, un phényle, un phénoxy, un phénylthio et un phénylamino ; où le groupe phényle est facultativement monosubstifué par un fluoro ; et
    R4 et R5, indépendamment, sont un hydrogène ou un alkyle en C1-C4 linéaire ou ramifié.
  3. Composé selon la revendication 1, dans lequel
    X est O, S, OCH2, CH2O ou CH2S ;
    Y est un hydrogène ou un cation inorganique pharmaceutiquement acceptable ;
    R2 est un substituant en position 2 ou 3 et est NHR4, NR4R5, un trifluorométhyle ou un trifluorométhoxy ;
    R3 est un hydrogène ; et
    R4 et R5, indépendamment, sont un hydrogène ou un alkyle en C1-C4 linéaire ou ramifié.
  4. Composé selon la revendication 1, dans lequel
    X est O, S, OCH2, CH2O ou CH2S ;
    Y est un hydrogène ou un cation inorganique pharmaceutiquement acceptable ;
    R2 est un substituant en position 2 et est un n-propylamino, un di-(n-propyl)amino, un trifluorométhyle ou un trifluorométhoxy ; et
    R3 est un hydrogène.
  5. Composé selon la revendication 1, dans lequel
    X est OCH2 ;
    Y est un hydrogène ou un cation inorganique pharmaceutiquement acceptable ;
    R2 est un substituant en position 2 et est un trifluorométhyle ; et
    R3 est un hydrogène.
  6. Composé selon la revendication 1, dans lequel X est O ;
    Y est un hydrogène ou un cation inorganique pharmaceutiquement acceptable ; et
    R2 et R3 sont des substituants aux positions 3 et 5, et sont un trifluorométhyle.
  7. Composé selon la revendication 1, choisi parmi
    l'acide 2-(cyclopropanecarbonyl-amino)-5-(2-trifluorométhyl-benzyloxy)-benzoïque ;
    l'acide 2-propionylamino-5-(2-trifluorométhylbenzyloxy)-benzoïque ;
    l'acide 5-(3,5-bis-trifluorométhyl-phénoxy)-2-cyclopropanecarbonylamino-benzoïque ; et
    l'acide 5-(3,5-bis-trifluorométhyl-phénoxy)-2-propionylamino-benzoïque et les sels de ceux-ci avec un cation inorganique pharmaceutiquement acceptable.
  8. Composition pharmaceutique comprenant un composé selon l'une quelconque des revendications 1 à 7 en tant qu'ingrédient actif, en association avec des excipients pharmaceutiquement acceptables.
  9. Composition pharmaceutique selon la revendication 8, dans laquelle l'ingrédient actif est présent en une quantité donnant une posologie quotidienne de 0,005 mg/kg à 10 mg/kg de poids corporel, en particulier de 0,025 mg/kg à 2 mg/kg de poids corporel.
  10. Composition pharmaceutique selon l'une quelconque des revendications 8-9, sous la forme d'une solution, d'une suspension, d'émulsions, d'un comprimé, d'une capsule ou d'une poudre pour l'administration orale, d'une solution stérile pour l'administration parentérale, d'un suppositoire pour l'administration rectale ou d'une formulation topique.
EP05707941A 2004-02-06 2005-02-04 Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh Active EP1720825B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL05707941T PL1720825T3 (pl) 2004-02-06 2005-02-04 Pochodne kwasu antranilowego, sposoby ich wytwarzania oraz zastosowanie jako inhibitorów DHOH

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0400234A SE0400234D0 (sv) 2004-02-06 2004-02-06 New compounds, methods for their preparation and use thereof
PCT/EP2005/050482 WO2005075410A1 (fr) 2004-02-06 2005-02-04 Nouveaux composes, procedes destines a leur preparation et utilisation correspondante

Publications (2)

Publication Number Publication Date
EP1720825A1 EP1720825A1 (fr) 2006-11-15
EP1720825B1 true EP1720825B1 (fr) 2008-07-09

Family

ID=31885234

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05707941A Active EP1720825B1 (fr) 2004-02-06 2005-02-04 Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh

Country Status (19)

Country Link
US (1) US7074831B2 (fr)
EP (1) EP1720825B1 (fr)
JP (2) JP5280634B2 (fr)
KR (1) KR101167142B1 (fr)
CN (1) CN1914152B (fr)
AT (1) ATE400547T1 (fr)
AU (1) AU2005210052B2 (fr)
BR (1) BRPI0507390A (fr)
CA (1) CA2552942A1 (fr)
DE (1) DE602005008016D1 (fr)
ES (1) ES2310333T3 (fr)
IL (1) IL176707A (fr)
NO (1) NO20063974L (fr)
NZ (1) NZ548619A (fr)
PL (1) PL1720825T3 (fr)
RU (1) RU2006132071A (fr)
SE (1) SE0400234D0 (fr)
WO (1) WO2005075410A1 (fr)
ZA (1) ZA200606321B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
RU2394021C2 (ru) * 2004-12-07 2010-07-10 Тояма Кемикал Ко., Лтд. Новое производное антраниловой кислоты или его соль
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
CN107235980A (zh) 2006-05-04 2017-10-10 勃林格殷格翰国际有限公司 多晶型
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
CA2677457A1 (fr) 2007-02-06 2008-08-14 Helen Tuvesson Andersson Nouveaux composes, leurs procedes de fabrication et leur utilisation
ES2315185B1 (es) * 2007-08-10 2010-01-13 Laboratorios Almirall S.A. Nuevos derivados del acido azabifenilaminobenzoico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
US7866852B2 (en) * 2007-08-29 2011-01-11 Texas Instruments Incorporated Heat sinks for cooling LEDs in projectors
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
EP2135610A1 (fr) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2239256A1 (fr) 2009-03-13 2010-10-13 Almirall, S.A. Sel de sodium de l'acide 5-cyclopropyl-2-{[2-(2,6-difluorophényl)pyrimidin-5-yl]amino}benzoïque en tant qu'inhibiteurs de la DHOD
US9006454B2 (en) * 2009-04-02 2015-04-14 Merck Serono S.A. Dihydroorotate dehydrogenase inhibitors
EP2314577A1 (fr) 2009-10-16 2011-04-27 Almirall, S.A. Procédé de fabrication de l'acide 2-[(3,5-difluoro-3'-méthoxy-1,1'-biphényl-4-yl)amino]nicotinique
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP5705239B2 (ja) * 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US10016402B2 (en) 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
EP2672963A4 (fr) 2011-02-08 2015-06-24 Childrens Medical Center Méthodes de traitement d'un mélanome
WO2013171167A1 (fr) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique
CN103788020B (zh) * 2014-01-22 2015-11-04 苏州明锐医药科技有限公司 沃替西汀的制备方法
WO2017211979A1 (fr) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinaisons de linagliptine et de metformine
CN111183129B (zh) * 2017-08-07 2024-07-23 国立大学法人广岛大学 新型邻氨基苯甲酸系化合物、使用了该化合物的Pin1抑制剂、炎症性疾病及癌症的治疗剂
EP3965753A1 (fr) 2019-05-07 2022-03-16 Universität Hamburg Inhibiteurs de dhodh et leur utilisation en tant qu'agents antiviraux
EP3992182A1 (fr) 2020-10-28 2022-05-04 Cisbio Bioassays Complexes d'europium(iii) en tant que capteurs de ph
EP4119138A1 (fr) 2021-07-12 2023-01-18 Universität Hamburg Inhibiteurs de dhodh et leur utilisation en tant qu'agents antiviraux

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2064305A1 (en) 1970-12-29 1972-07-06 Farbenfabriken Bayer Ag, 5090 Leverkusen Anthranilic acid esters alkylated on the nucleus
US4307113A (en) 1978-04-20 1981-12-22 Sandoz, Inc. Anthranilic acid derivatives
DE3161456D1 (en) 1980-02-06 1983-12-29 Hoffmann La Roche Process for the preparation of anthranilic acid derivatives
NO174506B (no) 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
HUT60458A (en) * 1991-02-01 1992-09-28 Sandoz Ag Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same
AU704544B2 (en) * 1995-03-14 1999-04-29 Novartis Ag Trisubstituted phenyl derivatives
WO1997028118A1 (fr) 1996-02-05 1997-08-07 Hoechst Celanese Corporation Procede de preparation d'acides anthreniliques
MXPA04000224A (es) * 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10254872A1 (de) 2002-11-25 2004-06-03 Symrise Gmbh & Co. Kg Anthranilsäureamide und deren Derivate als kosmetische und pharmazeutische Wirkstoffe

Also Published As

Publication number Publication date
JP5280634B2 (ja) 2013-09-04
IL176707A (en) 2011-04-28
RU2006132071A (ru) 2008-03-20
BRPI0507390A (pt) 2007-07-10
WO2005075410A1 (fr) 2005-08-18
AU2005210052B2 (en) 2010-12-23
ATE400547T1 (de) 2008-07-15
NZ548619A (en) 2010-06-25
EP1720825A1 (fr) 2006-11-15
KR101167142B1 (ko) 2012-07-23
US7074831B2 (en) 2006-07-11
PL1720825T3 (pl) 2009-04-30
IL176707A0 (en) 2006-10-31
AU2005210052A1 (en) 2005-08-18
CA2552942A1 (fr) 2005-08-18
ES2310333T3 (es) 2009-01-01
JP2012144548A (ja) 2012-08-02
SE0400234D0 (sv) 2004-02-06
NO20063974L (no) 2006-09-05
KR20070042496A (ko) 2007-04-23
CN1914152A (zh) 2007-02-14
ZA200606321B (en) 2008-01-30
JP5379876B2 (ja) 2013-12-25
JP2007522144A (ja) 2007-08-09
US20050187297A1 (en) 2005-08-25
DE602005008016D1 (de) 2008-08-21
CN1914152B (zh) 2010-06-09

Similar Documents

Publication Publication Date Title
EP1720825B1 (fr) Derives de l'acide anthranilique, procedes destines a leur preparation et utilisation comme inhibiteurs de dhodh
US8461205B2 (en) Anthranilic acid derivatives
RU2584986C2 (ru) Агонисты протеинтирозинфосфатазы-1, содержащей домен гомологии-2 src, и способы лечения с применением указанных агонистов
JP2515486B2 (ja) 置換ジ−ｔ−ブチルシクロヘキサジエノン類
JPH10338658A (ja) レチノイド作用調節剤
US4835189A (en) Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
KR910002371B1 (ko) 치환된 디-t-부틸페놀 및 이것을 함유한 약학적 조성물
MXPA06007938A (es) Derivados delácido antranílico, métodos para su preparación y su uso como inhibidores de dhodh
US5066679A (en) Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
CA3065961A1 (fr) Inhibiteurs de rac1 et leurs utilisations pour induire une bronchodilatation
JPH051004A (ja) 安息香酸誘導体

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060830

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

RAX Requested extension states of the european patent have changed

Extension state: LV

Payment date: 20060830

17Q First examination report despatched

Effective date: 20070620

RTI1 Title (correction)

Free format text: ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FRITZON, INGELA

Inventor name: JOENSSON, STIG

Inventor name: WELLMAR, ULF

Inventor name: ANDERSSON, GUNNAR

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: LV

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 602005008016

Country of ref document: DE

Date of ref document: 20080821

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: CHELSEA THERAPEUTICS INC.

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: CHELSEA THERAPEUTICS INC.

Effective date: 20080910

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2310333

Country of ref document: ES

Kind code of ref document: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081109

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081009

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20090216

Year of fee payment: 5

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

26N No opposition filed

Effective date: 20090414

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081010

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090204

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20110111

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: CHELSEA THERAPEUTICS INC.

Free format text: CHELSEA THERAPEUTICS INC.#13950 BALLANTYNE CORPORATE PLACE, SUITE 325#CHARLOTTE, NC 28277 (US) -TRANSFER TO- CHELSEA THERAPEUTICS INC.#13950 BALLANTYNE CORPORATE PLACE, SUITE 325#CHARLOTTE, NC 28277 (US)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602005008016

Country of ref document: DE

Owner name: CHELSEA THERAPEUTICS INC., US

Free format text: FORMER OWNER: ACTIVE BIOTECH AB, LUND, SE

Effective date: 20111213

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20120221

Year of fee payment: 8

Ref country code: CH

Payment date: 20120214

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120131

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120215

Year of fee payment: 8

Ref country code: RO

Payment date: 20120113

Year of fee payment: 8

Ref country code: GB

Payment date: 20120201

Year of fee payment: 8

Ref country code: SE

Payment date: 20120215

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20120217

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120307

Year of fee payment: 8

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20080709

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20130204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130901

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130205

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20131031

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005008016

Country of ref document: DE

Effective date: 20130903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130204

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130204

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20140408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130204

REG Reference to a national code

Ref country code: PL

Ref legal event code: LAPE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130205